Compare KB Financial Group, Inc. (KB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Mesoblast Limited — how do they compare? KB Financial Group, Inc. trades at $121.96 (market cap $42.62B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: KB Financial Group, Inc. is far larger — about 24.4× Mesoblast Limited's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Mesoblast Limited for 14 Days on average.
| KB | MESO | |
|---|---|---|
Market Cap | $42.62B | $1.75B |
Volume | 164,291 | 239,027 |
Sector | Financials | Health |
52-Week High | $132.88 | $20.96 |
52-Week Low | $77.50 | $13.19 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $215.53T | $1.83B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and improving profitability metrics. Technical indicators suggest a neutral near-term outlook, while analyst sentiment leans cautious with a 66.7% hold rating. Recent news highlights institutional interest and positive momentum coverage from financial media.
The outlook for KB appears balanced with attractive valuation metrics including a P/E of 9.68 and P/B of 0.94 suggesting potential undervaluation. However, the mixed analyst consensus and elevated EV/EBITDA of 21.71 warrant caution. Key risks include exposure to South Korean economic conditions and banking sector volatility, while opportunities lie in continued earnings growth and dividend potential.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
